Ipsen Launches Dysport In US

Ipsen has launched Dysport in the US for the treatment of cervical dystonia in adults. Dysport is the latest addition to the Ipsen’s drugs already available in North America, both in endocrinology with Somatuline Depot and Increlex, and in neurology, with Apokyn.

Dysport (abobotulinumtoxinA) inhibits release of the neurotransmitter acetylcholine from peripheral cholinergic nerve endings, which reduces muscular spasm. The active ingredient in Dysport is a botulinum toxin type A, which acts at the level of the neuromuscular junction in the targeted muscle.

Dysport was approved by the FDA on 29 April 2009 for two separate indications, the treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain in both toxin-naïve and previously treated patients, and the temporary improvement in the appearance of moderate to severe glabellar lines in adults younger than 65 years of age.

Christophe Jean, executive vice president of operations at Ipsen, said: “The launch of Dysport in its therapeutic indication for the treatment of cervical dystonia in the US is undoubtedly a significant milestone to strengthen Ipsen’s presence in North America. We are very pleased to be able to offer physicians a new and important treatment option for their patients suffering from cervical dystonia. Dysport, together with Somatuline and Increlex, becomes Ipsen’s third product to be available globally. With the achievement of this key milestone, I wish to congratulate and thank the teams that are making this launch a reality thanks to their hard work and dedication reflective of an efficient organisation.”